Back to search
FDAFDA · Food and drugs·Recall number Z-2890-2026

Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic

Published August 12, 2026 · Recall initiated: July 6, 2026

Summary

FDA records medical device Class II recall Z-2890-2026, published August 12, 2026 and initiated July 6, 2026. Recalling firm: Siemens Healthcare Diagnostics, Inc.; Status: Ongoing; Reported quantity: 7018 units; Lot: All Lots within expiry/UDI: 00630414611099. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Processing of urine albumin assay on the CI analyzers may lead to the following issues: Falsely depressed Atellica CH Urea Nitrogen (UN_c) results; Falsely depressed Atellica CH Enzymatic Hemoglobin A1c (A1c_E) results; Increased rate of reaction cuvette QC failures and Delayed results due to QC failures.

What to do

Voluntary: Firm initiated

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Siemens Healthcare Diagnostics, Inc.
Distributor
Worldwide distribution - US Nationwide including Puerto Rico and the countries of Australia, Austria, Bahamas, Belgium, Brazil, Canada, Chile, Curacao, St. Eus, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Ireland, Israel,¿Italy,¿Latvia, Malaysia, Netherlands, New Zealand, Norway, Portugal, Republic of Korea, Romania, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, United®Kingdom.¿
Lot
All Lots within expiry/UDI: 00630414611099
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic recalled?

Yes. FDA published recall Z-2890-2026 on August 12, 2026. Reported hazard: Processing of urine albumin assay on the CI analyzers may lead to the following issues: Falsely depressed Atellica CH Urea Nitrogen (UN_c) results; Falsely depressed Atellica CH Enzymatic Hemoglobin A1c (A1c_E) results; Increased rate of reaction cuvette QC failures and Delayed results due to QC failures.

What should I do if I have this product?

Voluntary: Firm initiated